IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infection Authors: Sonia Arca-Lafuente, Violeta Lara-Aguilar, Manuel Llamas-Adán, Sergio Grande-García, Andrés Deza de la Casa, Luz Martín-Carbonero, Pablo Ryan, Ignacio de los Santos, Mariano Matarranz, Mª Ángeles Jiménez-Sousa, Amanda Fernández-Rodríguez, Verónica Briz Published: 2025 ABSTRACT Purposers12979860 polymorphism of the lambda 4 interferon (IFNL4) gene has been related with Hepatitis C Virus (HCV) spontaneous clearance (CC genotype favourable versus CT/TT). The implications of this polymorphism over chronic-HCV disease are unknown, particularly during Human Immunodeficiency virus (HIV) coinfection.MethodsObservational study in 118 people with HIV (PWH): 45 with HCV-chronic infection (CHC); 38 who spontaneously clear HCV (SC) and 35 never infected by HCV (HIV). Expression of surface markers was evaluated in CD4+ and CD8+ memory T cells by flow cytometry, and plasma markers were quantified by Luminex or ELISA.ResultsCHC individuals with CC genotype (CHC-CC) showed higher expression of markers suggestive of senescence (PD1/CD57) and activation markers (CD38/CD25) in CD8 + T-cell subpopulations, compared to CT/TT carriers. Similarly, significantly higher expression was observed in CD4+ and CD8+ T cells in CHC-CC than SC-CC and HIV-CC controls. Regarding plasma markers, CHC-CC group had higher levels of 19 plasma immune biomarkers compared to CT/TT carriers, and 16 relative to SC-CC, including pro- and anti-inflammatory cytokines, while oxidative stress slightly diminished in CHC-CC individuals.ConclusionsCC-carriage may result in premature cellular activation and senescence or impaired functionality during HCV chronic infection in PWH, which may be masked by their maintained plasma immune homeostasis during clinical monitoring.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-025-07070-5. Introduction Nearly 50 million people live with a chronic infection caused by Hepatitis C virus and over 1.0 million people suffer a new infection by HCV per year. HCV infection is most common among people with Human Immunodeficiency Virus (PWH). In fact, approximately 2.3 million (6.2%) of PWH are co-infected with HCV worldwide [1], which accelerates liver fibrosis and increases death risk [2]. Most of cases develop a chronic infection which may last several decades, but 15–45% of the cases spontaneously clear the virus within 6 months after the acute infection (Hepatitis C Key facts, WHO, 2023), although lower HCV clearance rates have been observed among PWH [3]. The mechanisms involved in HCV clearance are still unclear, but it is known that several epidemiological, clinical, and genetic factors have an influence over HCV resolution. Among genetic factors, the rs12979860 polymorphism of the lambda 4 interferon (IFNL4) gene has been associated with HCV clearance [4, 5]. The rs12979860 is in the intron 1 of INFL4 gene, previously known as IL28B or IFN-λ3 variant. The favourable genotype CC is in linkage disequilibrium (LD) with the rs368234815-TT genotype, which encodes a dysfunctional IFN-λ4 protein. The favourable genotype is associated with a higher prevalence of spontaneous clearance of HCV and a better response to previous treatments based on peginterferon (pegIFN) and ribavirin [6, 7]. Considering this, CC genotype was proposed as a predictive marker for HCV resolution [5, 8], compared with the unfavourable genotypes CT and TT. A strong immune response involving type I IFN is frequent during acute infection of HCV [9], and the efficacy of this response through viral elimination is probably favoured by certain genetic variants such as rs12979860 polymorphism. Nevertheless, an important percentage of individuals infected by HCV develops a chronic infection, that usually progress to cirrhosis and hepatocellular carcinoma. In PWH, inflammation and immune activation triggered by HCV also favours the progression of HIV infection, leading to immune exhaustion [10]. Additionally, senescent cells usually exhibit different forms of damage accumulation, such as DNA damage induced by reactive oxygen species (ROS) produced by mitochondria. Mitochondria dysfunctions are produced both by the interactions with HCV, and also by the inflammatory processes triggered after HCV infection [11]. Chronic HCV infection in PWH produces premature virus-induced senescence, accompanied by a pro-inflammatory phenotype called the Senescence-Associated Secretory Phenotype (SASP), which promotes rapid liver fibrosis progression and additional age-related comorbidities. Among them, a reduced proliferative capacity and telomere shortening is observed in T cells both in HCV and HIV infections [12, 13]. The cellular immune profile of people with the favourable CC genotype has not been described yet, and its putative impact on T-cell development and immunosenescence remains unknown, especially in HCV/HIV coinfected patients. Understanding the impact of PWH’s genetic background on the management of HCV infection would improve clinical management. The aim of this work is to assess whether CC-carriage could modify the immunophenotypes, oxidative stress and plasma immune profile in PWH that had also acquired HCV. This possible dysregulation may increase their risk of comorbidities and age-related disorders when they progress to HCV chronic disease. Material and methods Study design We carried out a multicentre observational study from the COVIHEP cohort (Supplementary Data 1) from four Public Spanish Hospitals in Madrid Autonomous Community. Samples were recruited on each hospital and processed at the National Center for Microbiology, Institute of Health Carlos III, Madrid (Spain). One hundred eighteen PWH with different statuses to HCV infection were enrolled: (1) 45 with active HCV‐chronic infection naïve to any HCV treatment (CHC group) [positive polymerase chain reaction (PCR) and positive HCV antibodies]; (2) 38 who spontaneously cleared HCV within 6 months of HCV infection [spontaneous clearers (SC) group] (negative PCR and positive HCV antibodies, in the absence of anti‐HCV treatment); (3) 35 HIV mono-infected patients without evidence of previous HCV infection (HIV group) (negative PCR and negative HCV antibody). SC and HIV were used as control groups. All patients received suppressive antiretroviral treatment (ART) during at least 1 year and were undetectable for HIV during the previous year, with CD4+ T‐cells counts ≥ 500 cells/mm3 since at least 1 year before sample collection. Exclusion criteria are detailed in Supplementary Data 2. Clinical and epidemiology data were obtained from medical records. Biological material Peripheral Blood Mononuclear Cells (PBMCs) were isolated from whole blood by density gradient centrifugation method with Lymphoprep™ and SepMate™ tubes (Stemcell Technologies) and stored at viability until use. Plasma was clarified by centrifugation at 10 000 × g for 10 min at 4 °C and stored at − 80 °C until use. rs12979860 genotyping Total DNA was extracted from PBMCs using Allprep® DNA/RNA Mini Kit (Qiagen, Hilden, Germany). Genotype of the rs12979860 polymorphism was determined by real time PCR. DNA was amplified with the Premix Ex Taq (TAKARA) and the TaqMan® SNP Genotyping Assay (ID C___7820464_10, ThermoFisher) in a 7500 Fast (Applied Biosystem), following the manufacturer instructions. Each patient was classified in two study groups: (1) favourable genotype (CC); (2) and unfavourable genotype (CT/TT). T-cell immunophenotype assessment The expression of activation (CD25, HLA-DR, and CD38), terminal exhaustion and senescence (PD1 and CD57), and Treg (FOXP3, CD127) markers was evaluated in CD4+ and/or CD8+ memory T cells by flow cytometry using an Aurora Spectral Flow Cytometer with five lasers (Cytek Biosciences) (Supplementary Data 2), in a subset of cells (CHC = 26, SC = 22, HIV = 26). Data were analyzed with FlowJoTMv10 software (Tree Star), and the resulting values for each subpopulation were given as proportional to their reference population. The gating strategy used is available at Supplementary Data 3. Oxidative stress level in plasma To characterize oxidative-stress levels, we measured the plasma concentration of different reactive oxygen species (ROS) markers (at DNA, protein, and lipid level), total antioxidant capacity (TAC), reduced glutathione (GSH) and oxidized glutathione (GSSG), and relative telomere length of PBMCs (RTL). Details of the methodology used can be found in Supplementary Data 2. Plasma immune profile We assessed a selection of 45 immune response biomarkers, 26 of them associated to SASP, including cytokines, chemokines, and growth factors [14, 15]. All biomarkers were analyzed with a multiplex immunoassay (Luminex xMAP technology). The complete list is available in Supplementary Data 4. The measured raw fluorescence intensity (FI) values (arbitrary units, a.u.) were used as previously described [16, 17]. Statistical analysis For the descriptive study of clinical and epidemiological data of the patients belonging to each infection group, continuous variables were summarized by rs12979860 genotype (CC vs CT/TT) as median, and categorical as frequency and percentage. With the aim of determining the association of CC genotype with an altered immune system in PWH with chronic HCV infection, first, both cellular, oxidative stress, and plasma immune markers levels were compared between favourable and unfavourable genotypes within each infection group. Secondly, immune markers levels were compared between CHC-CC carriers vs. control groups (SC and HIV) carrying CC genotype. Significant differences between categorical data were calculated using the χ2 test or Fisher’s exact test for each infection group. Mann–Whitney U tests (two-sample Wilcoxon tests) were used to compare continuous variables. To estimate differences in cellular markers, we carried out a Generalized Additive Model for Location, Scale and Shape (GAMLSS) with a zero-and-one-inflated beta (BEINF) distribution, adjusted for age with a stepwise approach using the Akaike Information Criterion (AIC). This approach appropriately models the statistical properties of proportional cytometry data, which frequently include absolute zeros, meaning a complete absence of a cellular subset for some subjects [18]. In addition, GAMLSS model tests whether differences between groups lie both in the average proportion of a subpopulation (location), and/or its biological variability across subjects (scale). We estimated differences in ROS damage and plasma immune biomarkers by a generalized linear model (GLM) with gamma distribution (log-link), adjusted for age with a stepwise approach. q-value ≤ 0.15 [p value corrected for the false discovery rate (FDR) by Benjamini–Hochberg correction] was considered significant. All markers’ data were integrated into a supervised multivariate analysis to confirm individuals clusterization in IFNL4 genotype groups, using a partial least squares discriminant analysis (PLS-DA) with mahalanobis distance computation. The final model performance was validated using leave-one-out cross-validation. Statistical software R (v 4.3.1) (http://www.r-project.org) was used for statistical analyses. Results Epidemiological and clinical characteristics of the patients Clinical and epidemiological characteristics of all patients are shown in Supplementary Data 5. Overall, the median age was 50 and 44.07% were female. Regarding HCV status, 38.14% belonged to CHC group, 32.20% to SC group and the rest were HIV monoinfected. As expected, higher frequency of CC carriage was observed among SC group (76.32%, n = 29/38), 2.5 times higher than in CHC group (31.11%, n = 14/45). A homogeneous distribution was observed for HIV control group (51.43% with CC genotype, n = 18/35). The median time since HCV spontaneous clearance in SC patients was 9.55 (7.85–12.67) years. Regarding the metabolic characteristics, significant differences were observed only in CHC group. In particular, 70.00% of CHC individuals carrying CC genotype presented LDL levels higher than 130 mg/dL (p = 0.002), and the liver function marker GGT was significantly increased in the unfavourable CT/TT genotype within CHC group, although there were no differences in liver fibrosis scores such as APRI, FIB-4 and fibroscan (Supplementary Data 6). Molecular characterization between favourable (CC) and unfavourable (CT/TT) rs12979860 genotypes in CHC individuals With the aim of assessing the immunological implications of CC genotype in PWH who developed chronic HCV infection, favourable and unfavourable IFNL4-rs12979860 genotypes within CHC group were compared. Immunophenotype characterization The most notable differences concerned CD8+ T-cell populations in CHC group, while regarding CD4+ T cells, only resting EM Th0/Th1 subpopulation was significantly different between CHC genotypes, decreasing in CC carriers (Supplementary Data 7). Higher levels of total CD8+ T cells and CD8+ EM3 cell subpopulation were observed among CHC-CC carriers compared to CT/TT genotypes, while levels of CD8+ EM1 and EM4 cells were significantly reduced within CC genotype (Fig. 1). Regarding CD8+ T activation markers, CC carriers showed significantly higher expression of middle (CD25+ HLADR+) and late (CD38+ HLADR+) activation markers at distinct cell differentiation stages (middle activation in EM, EM1 and EM4, and late activation in the total fraction, and EM). Additionally, total expression of CD25 and CD38 surface markers was evaluated. As shown in Supplementary Data 8, the same trend was observed for CHC-CC carriers. On the contrary, resting CD8+ T cells showed a reduction of about 50% among CHC-CC carriers, statistically significant in EM, and TEMRA subpopulations. With respect to CD8+ T-cell senescence of CHC group, CC carriers showed remarkably higher expression than CT/TT carriers of PD1+ /CD57+ in all subpopulations, significant for effector memory (EM, EM2, and EM3) and TEMRA (pE2) cells. The full dataset of the populations with significant differences can be accessed in Supplementary Data 7.Fig. 1Comparison of immunophenotypes between CC genotype versus CT/TT within CHC group. Values are expressed as arithmetic median ratio adjusted for age (aAMR) with a 95% confidence interval (CI95%) obtained using a GAMLSS model. Only statistically significant populations are depicted (p < 0.05, q < 0.15) Comparison of immunophenotypes between CC genotype versus CT/TT within CHC group. Values are expressed as arithmetic median ratio adjusted for age (aAMR) with a 95% confidence interval (CI95%) obtained using a GAMLSS model. Only statistically significant populations are depicted (p < 0.05, q < 0.15) Within the control HIV group, only CD8+ EM subpopulation showed significant differences [aAMR = 0.58 (0.41–0.81), p = 0.005, q = 0.060]. No significant differences were observed for Treg cell subsets between any comparison group (data not shown). Oxidative stress and plasma immune profile characterization Subsequently, we explored the differences in oxidative stress, and plasma immune biomarkers, between favourable (CC) and unfavourable (CT/TT) genotypes in CHC group. With respect to oxidative stress markers, our data showed an increased ratio of GSH/GSSG in CC genotype within CHC group, accompanied by a significant decrease in GSSG levels, and a significant reduction in lipid-soluble antioxidants levels compared to CT/TT genotypes (Fig. 2, Supplementary Data 9). No significant differences were found between genotypes for SC and HIV control groups (Supplementary Data 10 and 11).Fig. 2Boxplot representation of relative telomere length (RTL) and oxidative stress markers that showed significant differences between infection groups with CC or CT/TT genotypes. Significant values were obtained using a GLM adjusted by de most significant variables; *: p < 0.05 and q < 0.15. Lower and upper hinges correspond to first and third quartiles, and whiskers extend from the hinge to the smallest or largest value at most 1.5 times the interquartile range (IQR). Abbreviations: GSH, reduced glutathione; GSSG, oxidized glutathione; LP, lipid peroxidation Boxplot representation of relative telomere length (RTL) and oxidative stress markers that showed significant differences between infection groups with CC or CT/TT genotypes. Significant values were obtained using a GLM adjusted by de most significant variables; *: p < 0.05 and q < 0.15. Lower and upper hinges correspond to first and third quartiles, and whiskers extend from the hinge to the smallest or largest value at most 1.5 times the interquartile range (IQR). Abbreviations: GSH, reduced glutathione; GSSG, oxidized glutathione; LP, lipid peroxidation Regarding plasma immune response biomarkers, we observed significantly higher levels of 14 cytokines in CHC individuals carrying CC genotype compared to CT/TT genotypes, as shown for SASP cytokines GM-CSF, IL-1 beta, IL-1RA, IL-2, IL-6, IL-7, IL-13, IL-15, and TNF-alpha, and for non-SASP related cytokines IL-4, IL-10, IL-17A, IL-27, and IL-31. Plasma levels of the SASP chemokines Eotaxin and MCP-1, as well as the growth factors EGF, FGF-2, and LIF were also significantly higher in CHC patients with CC genotype versus CT/TT. With respect to SC and HIV control groups, no significant differences were found between genotypes (Fig. 3; Supplementary Data 10 and 11).Fig. 3Boxplot representation of the plasma immune biomarkers that showed significant differences between infection groups with CC or CT/TT genotypes. Biomarkers are distributed as cytokines (a), chemokines (b), and growth factors (c). SASP related markers are shaded in purple. Significant values were obtained by GLM adjusted by de most significant variables; *: p < 0.05 and q < 0.15. Lower and upper hinges correspond to first and third quartiles, and whiskers extend from the hinge to the smallest or largest value at most 1.5 times the interquartile range (IQR) Boxplot representation of the plasma immune biomarkers that showed significant differences between infection groups with CC or CT/TT genotypes. Biomarkers are distributed as cytokines (a), chemokines (b), and growth factors (c). SASP related markers are shaded in purple. Significant values were obtained by GLM adjusted by de most significant variables; *: p < 0.05 and q < 0.15. Lower and upper hinges correspond to first and third quartiles, and whiskers extend from the hinge to the smallest or largest value at most 1.5 times the interquartile range (IQR) Integrative PLS-DA modelling of cellular, oxidative stress and plasma immune profile Finally, we performed an integrative PLS-DA model to assess the clusterization of CHC individuals into CC or CT/TT rs12979860 genotypes based on their immune profile (T-cell immunophenotype, oxidative stress, and plasma immune profile). PLS-DA analysis showed that the whole set of immune markers properly discriminates between CHC individuals with CC genotype versus CT/TT (Fig. 4a), with an AUROC = 0.914 (p < 0.001). Moreover, we determined the VIP scores for each immune marker from PLS-DA analysis. Markers with VIP score > 3 were considered significant, which included: the GSH/GSSG ratio, a total of 9 plasma immune biomarkers (IL-2, IL-4, IL-10, IL-15, IL-17A, TNF-alpha, MCP-1, EGF, and Eotaxin), and 8 different CD8+ T-cell subpopulations [EM1, EM3 and EM4, subpopulations expressing middle activation (total, EM, and TEMRA pE2), and terminal exhaustion and senescence (total, and EM) markers]. Consistently, immune markers that showed significant different after regression model analysis, presented also the highest VIP scores from PLS-DA (Fig. 4b).Fig. 4Supervised multivariate analysis of the complete panel of immune markers for CHC group. Results of partial least squares discriminant analysis (PLS-DA) classification of CHC individuals into CC -pink circles- or CT/TT genotype groups -blue triangles- (a). Immune markers with the highest VIP scores (> 3) from PLS-DA model (b) Supervised multivariate analysis of the complete panel of immune markers for CHC group. Results of partial least squares discriminant analysis (PLS-DA) classification of CHC individuals into CC -pink circles- or CT/TT genotype groups -blue triangles- (a). Immune markers with the highest VIP scores (> 3) from PLS-DA model (b) Analysis of the immune profile of CC carriers between infection groups Once we determined that the individuals of CHC group showed several differences in immune markers depending on their rs12979860 genotype while control groups did not, we aimed to analyse whether CHC-CC carriers immune profile differed from control groups carrying CC genotype. With this purpose, we compared the immune profile of CHC individuals carrying CC genotype with the CC-carriers of control groups (Supplementary Data 12 and 13). Comparison of T-cell immunophenotype of CC carriers between infection groups First, we compared the CD4+ and CD8+ cellular populations of CHC-CC carriers with PWH with CC genotype that had achieved HCV elimination (SC-CC group). Eighteen cellular populations showed differential levels between CHC-CC and SC-CC groups, 16 of them belonging to CD4+ T-cell fraction (Supplementary Data 13. Compared to SC-CC controls, CD4+ total fraction was significantly lower in CHC-CC group, as well as their central memory (CM) levels, and EM Th0/Th1 fraction. However, EM Th1/Th2 levels were significantly higher for CHC-CC carriers compared to SC-CC. Regarding cells on terminal phase, an increase was observed for CD4+ TEMRA total fraction for CHC-CC group compared to SC-CC, including CD4+ TEMRA effector, and TEMRA CD38+ /HLADR+ subpopulation, indicative of late activation (Fig. 5a). On the contrary, TEMRA pE1 subpopulations diminished in CHC-CC carriers compared to SC-CC group. The most remarkable result was observed for CD4+ T-cell markers suggestive of advanced dysfunction and senescence (PD1+ /CD57+), that showed levels twice or even four times significantly higher in CHC-CC group versus SC-CC controls, comprising the total fraction, EM, TEMRA, and TEMRA pE1 subpopulations (Fig. 5a).Fig. 5Comparison of immunophenotypes between CHC-CC carriers versus SC-CC or HIV-CC control groups. Values are expressed as arithmetic median ratio adjusted for age (aAMR) with a 95% confidence interval (CI95%) obtained using a GAMLSS model. Only statistically significant populations for at least one comparison are depicted (*: p < 0.05 and q < 0.15) Comparison of immunophenotypes between CHC-CC carriers versus SC-CC or HIV-CC control groups. Values are expressed as arithmetic median ratio adjusted for age (aAMR) with a 95% confidence interval (CI95%) obtained using a GAMLSS model. Only statistically significant populations for at least one comparison are depicted (*: p < 0.05 and q < 0.15) Although only CD8+ T EM3 subpopulation reached significantly higher levels for CHC compared to SC group, a similar trend to increased cellular activation, terminal exhaustion and senescence was observed in CD8+ T cells among CHC-CC carriers (Fig. 5b). On the other hand, CD8+ EM4 showed significantly lower levels in CHC group in contrast to SC controls carrying CC genotype. To examine whether CC-genotype carriage was associated with an altered immunophenotype in CHC in contrast to PWH who have never been acutely infected by HCV, cellular populations were compared among CHC-CC and HIV-CC groups (Supplementary Data 13). Again, CHC-CC group showed significantly lower levels of CD4+ T cells compared to HIV-CC (Fig. 5a). Nevertheless, the rest of the significant differences observed were on account of CD8+ T cells, with a similar trend than the observed against SC-CC control group. Precisely, CD8+ EM1, EM4 and middle activated TEMRA effector cells were significantly reduced in CHC-CC compared to HIV-CC controls. Opposite, CHC-CC individuals showed higher levels than HIV-CC controls of total CD8+ T-cell fraction, EM, EM3, and subpopulations expressing late activation (CD8+ total fraction, EM, EM3, TEMRA, and TEMRA effector) and terminal exhaustion and senescence (CD8+ total fraction, EM, and TEMRA pE2) markers, as shown in Fig. 5b. A similar trend was observed after the evaluation of total CD25+ and CD38+ cellular populations (Supplementary Data 14 and 15). No significant differences were observed for Treg cell subsets between any comparison group (data not shown). Comparison of oxidative stress and plasma immune profile of CC carriers between group of infection Subsequently, we analyzed the oxidative stress and plasma immune profile of CHC individuals carrying favourable CC genotype against control infection groups. We did identify significant differences between CC carriers of CHC compared to SC group, although any significant differences were observed between CC carriers of CHC group compared to HIV controls (Supplementary Data 16 and 17). A total of three oxidative stress markers were significantly different between CHC and SC group within those with CC genotype: a reduction of lipid peroxidation, and higher levels of nitrate and GSH/GSSG ratio were observed in CHC-CC patients (Fig. 2). Additionally, relative telomere length (RTL) was lower in CHC group compared to SC. We identified 16 plasma immune biomarkers with a significant increase in CHC with CC genotype in comparison with SC (Fig. 3). They comprehended a total of 11 SASP markers: cytokines GM-CSF, INF-gamma, IL-1 beta, TNF-alpha, IL-1RA, IL-7, and IL-15; and chemokines Eotaxin, IP-10, MCP-1, and MIP-1 alpha. The anti-inflammatory cytokines IL-4, IL-10, IL-17A, and IL-27, and the growth factor LIF were also significantly increased in CHC-CC compared to SC-CC. Discussion To our knowledge, this is the first study that integrates an analysis of the immunophenotype, and plasma levels of oxidative stress and immune biomarkers between the different IFNL4-rs12979860 genotypes in HCV/HIV coinfected individuals, identifying an increase in CD8+ T-cell population, activation and exhaustion as well as in plasma levels of both pro- and anti-inflammatory cytokines in CHC-CC carriers. Among our study cohort, the CC genotype of the rs12979860 polymorphism was mainly found in SC-PWH, while keeping lower presence in CHC and a homogeneous distribution in HIV, which confirmed the association between the favourable genotype CC with a spontaneous resolution of HCV. In particular, SC prevalence was threefold higher between CC than CT/TT genotype, in agreement with previous studies [4, 5]. Regarding the biochemical profile, LDL levels, usually lower in individuals with chronic HCV infection [19], were significantly higher in CHC-CC carriers, in agreement with previous studies [20], indicating that CHC patients with cardiovascular risk may require lipid lowering treatment depending on their CC carriage [21]. After analysis of the immunophenotype, we found an overall increase of CD8+ T-cell fraction among CC carriers in CHC group. Concretely, these individuals showed higher levels of CD8+ T-cell activation, immune exhaustion and senescence, both in EM subpopulations and TEMRA cells. Considering that viral escape mutations occur in CD8+ T-cell epitopes, the inability to eliminate HCV virus of CHC group despite rs12979860 genotype could be a consequence of the presence of HCV escape mutations [22–24]. The impact of the higher level of CD8+ T cells on the liver cytotoxic response in our cohort's is unknown, but previous studies have shown that cytotoxic responses observed in the liver mostly translate to peripheral blood [25]. The exhausted and senescent cellular immune response observed in CD8+ T cells of CHC-CC carriers reflects the persistent, but not yet sufficient, immunological response associated with CC genotype during chronic infection in peripheral blood. Our results are in accordance with the in vitro evaluation performed by Coto-Llerena et al. (2020) in CD8+ T cells obtained from liver tissue of CHC patients. They observed increased levels of expression of the senescence marker CD57 in individuals with IFN-λ4 non-producer genotype (genotype rs368234815-TT, which is in LD with rs12979860-CC). In line with us, the authors did not find any significant differences in CD4+ T cells. Thus, even though we could not confirm antigen-specific stimulation in our cohort, our results may suggest that, once HCV infection develops into a chronic disease, CC carriers initiate an accelerated activation to try to eliminate HCV that leads to premature cell exhaustion, which could be interpreted as unfavourable in terms of immune cellular function in PWH. The reason behind may be a persistent antigenic stimulation of CD8+ T cells, which would be deficient under higher IFN-λ4 production in CT/TT carriers due the inhibition of the signalling pathway of IFN lambda (IFNL) family genes [7, 26]. In our cohort, this leads to advanced dysfunction and senescence of CD8+ EM2 and EM3 populations in HCV-chronic individuals with CC genotype, which would imply a worse prognosis in future. This hypothesis would be supported by the fact that chronic patients who develop cancer show defective granzyme B production [27, 28] which is mainly released by CD8+ T EM2 and EM3 cells, and a representative marker for the priming of immunity and efficient killing of tumour cells. In the absence of HCV antigen-specific data, an alternative hypothesis warrants consideration. As our study population consist of PWH, it is possible that HIV-induced immune dysregulation is the primary driver of both the failure to clear HCV in some CC-genotype individuals and the subsequent immunophenotype we observed. In this scenario, the bystander cellular activation and senescence would be a biomarker for a low probability of spontaneous clearance, rather than a consequence of the chronic infection itself. However, previous studies showed that coinfection with HIV did not alter the correlation between CC genotype and HCV clearance [4]. Considering that all individuals in our cohort are PWH, the increased late activation and immunophenotype suggestive of advanced dysfunction and senescence in terminal subpopulations of both CD4+ and CD8+ T cells in CHC-CC carriers compared to SC and HIV controls carrying CC genotype is most likely driven by a persistent HCV infection rather than to HIV dysregulation exclusively. To certainly discard immune dysregulation at baseline as cofounding factor, it would have been crucial to study the immunophenotypes of our cohort prior to HCV infection. Thus, the data suggest that, although HIV may set the stage, it is persistent HCV infection in CC carriers that drives the observed specific enhanced immunosenescence profile, highlighting that this phenotype is not exclusively due to HIV dysregulation. Regarding oxidative stress markers, increased oxidative stress is an indicative of hepatic disease progression as a result of chronic inflammation, which promotes liver damage and extrahepatic complications [29]. Our data showed that CC carriers of the CHC group exhibited reduced ROS species. In particular, CC carriers showed lower levels of GSSG and higher levels of GSH/GSSG ratio among CHC, a marker of reduced oxidative stress, together with lower lipid peroxidation levels. Hence, the reduced oxidative stress among HCV chronic patients with CC genotype would be related with an improved ability to buffer the excess oxidative stress generated by chronic HCV infection which could lead to a better prognosis of HCV infection in PWH. In fact, CHC individuals with CC genotype showed significantly lower levels of GGT, which may reflect lower liver damage, although, no differences in liver fibrosis status were observed by APRI, FIB4 or fibroscan, in disagreement with the a previous study in mono-infected individuals, in which increased hepatic inflammation and fibrosis were observed in CC-carriers [30]. However, discrepant results can be found in literature regarding association of CC genotype with fibrosis [31, 32]. Previous studies reported that liver fibrosis progression seems to be mediated by oxidative stress factors, as well as high correlation between hepatic stellate cell activation and hepatocyte senescence has been observed [33]. Based on that, we propose that the reduced oxidative stress displayed by CC carriers in PWH, might be associated with a lower liver fibrosis progression in the future in these individuals. However, despite the improved oxidative stress profile of CHC-CC carriers, these individuals did still not reach ROS levels of SC controls, as additional senescence markers such as telomere length shortening or nitrate levels, were still more remarkable in CHC group compared to SC with CC genotype. Our results show that CHC-CC carriers have higher levels than CT/TT carriers of both pro-inflammatory cytokines related to SASP, including GM-CSF, IL-1beta, IL-6, TNF alpha [15], and the chemokine Eotaxin [34], as well as anti-inflammatory cytokines such as IL-4, IL-13, and IL-10. Additionally, most of the mentioned cytokines showed also higher levels than CC carriers of the control SC group. These results are congruent with the cellular immune profile exhibited by CHC-CC carriers, since IL-1 beta, IL-6, and TNF-alpha are a primary byproduct of CD8 + TEMRA cells secretion [35], cell population that showed increased activation levels among CHC-CC carriers compared to control groups. Likewise, CD4+ T EM Th1/Th2 subpopulations, which were significantly higher among CHC-CC compared to SC-CC, are key producers of the elevated IL-4 cytokine [36]. The CHC-CC group also showed augmented levels of cytokines IL-2, IL-7 and IL-15, described to have a potential role in CD8+ T cells long-term maintenance during viral chronic infections [37], which might be related with the higher activation, exhaustion and senescence of the CD8+ T cells observed in CHC-CC carriers. Besides, beneficial actions of the increased pro-inflammatory cytokines have also been described against HCV and HIV infections. IL-15 can take control over HCV replication in the liver [38], while GM-CSF marker reduced HCV viremia after administration to people with HCV [39], and promoted immune response against infective agents such as HIV [40]. Anti-inflammatory drugs have shown to reduce oxidative stress and prevent the development of long-term cirrhosis [41]. The increased production of anti-inflammatory cytokines observed in CHC patients associated with CC genotype may have a homologous effect, preventing the progression of the infection by controlling the oxidative stress status, opposite to CT/TT carriers. Concretely, IL-10 has been described to inhibit pro-inflammatory cytokine production associated with SASP [42–44], so it may be involved in homeostasis maintenance. Boisvert & Shoukry have described that favourable CC genotype is associated with a more controlled IFNL production and induction of interferon-stimulated genes, while unfavourable CT/TT genotypes present higher IFN-λ production that leads to inhibition of the IFN signalling pathway [26]. Since IL-10 is genomically and structurally related to IFNL family, similar induction mechanisms may act during HCV viral infection, preventing tissue damage and contributing to the control of liver disease progression [45]. However, IL-10 demonstrates a notable dualistic role in the immunopathology of HCV infection. Conversely, elevated levels of this cytokine have been implicated in the establishment of chronic HCV infection in PWH [46, 47]. This detrimental effect is attributed to its capacity to suppress the Th1 immune response, a critical component for effective viral clearance [48, 49]. Consequently, while IL-10's anti-inflammatory properties may reduce liver pathology, they may also facilitate viral persistence by dampening the specific immune responses required to eradicate the virus. On the other hand, some growth factors levels were higher in CC carriers of CHC group. To our knowledge, no previous association of growth factors levels and rs12979860 polymorphism has been described up to date. The role of growth factors along HCV infection is still unclear, previous studies reported that FGF-2 triggers HCV replication and is associated with high viral loads [50]. Additionally, we also observed that EGF was higher in CC carriers of CHC individuals, which might be related to the higher need of an increased liver tissue repairment and cellular proliferation [51], and led to hepatocellular carcinoma and development of other type of cancers. Collectively, the multivariate PLS-DA analysis not only confirmed the ability to classify CHC individuals based on their rs12979860 genotype but also identified the key factors driving this distinction. Notably, the immune markers with the highest discriminatory power (VIP score > 3) comprise a heterogeneous mix of immune system components. Leading the contributors were the chemokine Eotaxin, closely followed by exhaustion and senescence markers on CD8+ effector memory T cells (CD8+ EM PD1+ /CD57+), and cytokines traditionally considered anti-inflammatory, such as IL-10 and IL-4. This complex immunological profile, where signals for cellular recruitment, cellular exhaustion, and a robust anti-inflammatory response coexist, reinforces the hypothesis that HCV chronicity in CC carriers does not stem from an absence of an immune response, but rather from an intense yet dysregulated and ultimately ineffective response to clear the virus. We also compare our results with CC carriers of SC and HIV groups. The reason why these inter-genotype differences in plasma immune biomarkers of CC carriers are predominant in CHC compared to SC group may be the absence of an active HCV infection. Although no significant, the same trend was observed when compared to HIV controls. The precise reason why a small percentage of individuals carrying the favourable CC genotype fails to clear the virus remains unclear. Our results suggest this is not due to a lack of immune response, but rather an over-exuberant one that becomes dysfunctional. This failure could stem from multifactorial reasons, including a higher viral inoculum, the presence of HCV escape mutations or, as discussed, a greater degree of immune dysregulation at baseline due to HIV, leading to an ultimately ineffective response. In addition, the IFNL4-rs12979860 polymorphism has crucial implications for other diseases, not only for HCV. It has also been associated with a reduced severity of COVID-19 disease [52, 53], and increased clearance rates of other RNA viruses [54], indicating that the genetic background could predispose to a better handling of RNA viruses infection and/or coinfections in PWH. Overall, our results suggest that IFNL4 rs12979860-CC genotype involves an overstimulated immune response, increasing plasma levels of anti-inflammatory cytokines that may counteract the activity of immune senescence plasma proteins, thus protecting against excessive inflammation and preventing ROS damage in CHC-CC individuals. However, given the immunophenotype suggestive of senescence or impaired functionality observed in these individuals, rs12979860 genotyping should be considered during chronic HCV disease to identify CC-carriers that might be prone to develop age-related comorbidities. This specific group of individuals could benefit from a new clinical approach, the combination of immunosuppressive agents and antiviral treatment when starting therapy, which may offer a novel strategy to achieve better regulation of the cellular immune response through a reduction of inflammation levels. Prior to initiating treatment, potential drug-drug interactions should be carefully evaluated, given the documented interactions in post–liver transplant patients [55]. However, the safety profile of the combination of current ART, DAAs, and immunosuppressants has significantly improved, including in people with HIV/HCV co-infection [56]. Nevertheless, long-term immunosuppressive therapy should be carefully monitored in these individuals, since sustained immunosuppression may exacerbate CD8+ T-cell exhaustion. This cellular exhaustion would carry associated general age-related comorbidities such as increased risk of severe secondary viral infections [57], as well as additional disorders such as neurodegeneration [58], autoimmunity and cancer development [59–62], frequently observed in PWH. Further research along these lines is needed to clarify the benefits of immunotherapy in this group of individuals. As mentioned above, hypercholesterolemia and fibrosis progression should be also carefully monitored in CHC-CC along treatment to reduce the risk of comorbidities. To interpret those results correctly, we should bear in mind that all the individuals included in this study were PWH. This was a deliberated choice to investigate the interplay between IFNL4 genotype and HCV status in a coinfected population. While the absence of an HIV-seronegative control group means we cannot fully disentangle effects that are strictly dependent on HIV coinfection, this design provides a unique strength: a uniform population, all of them on ART and with CD4 counts over 500 cells/mm3. Therefore, the potential baseline dysregulations due to HIV are taken into consideration among all infection groups. Additionally, as mentioned above, previous studies showed that coinfection with HIV did not modify the correlation found between CC genotype and HCV clearance [4], so the same results may be expected on the analysis of immune response markers associated to IFNL4 genotypes in HIV seronegative controls. We should bear in mind that there was not an equally distribution of IFNL4-rs12979860 genotypes among groups of infection, which could introduce a bias in our results. However, this is an inherent outcome to the association of rs12979860-CC genotype with spontaneous HCV resolution as previously reported [6], and would be inevitably linked to the study design. The limited sample size for specific subgroups, could have limited the possibility of finding statistical significance in some comparisons, especially for SC with unfavourable genotype (CT/TT), composed of 9 individuals. We must also keep in mind the difficulties to find and get HCV clearers to clinic, due to the asymptomatic course of the infection on its acute phase. Although we accounted for the most significant clinical variables, additional confounders could be affecting our results. Lifestyle data such as smoking habits, diet, or sedentarism could not be recorded, their inclusion a in future research may be of value. Furthermore, since this is a cross-sectional study, we are unable to infer how the immune markers of CHC-CC individuals would behave over time, especially before HCV infection and after treatment with DAAs and successful elimination of HCV. Previous studies have reported partial normalization of inflammatory profile after the elimination of the virus both in HIV/HCV co-infected [63] and HCV mono-infected individuals treated with DAAs [64], although cirrhosis status seams to play an important role in the immune recovery [65]. Regarding CD8+ T-cell exhaustion, it remained higher in coinfected individuals after treatment [66], although we could not find any studies on the association with IFNL4 genotype. Further studies recruiting a larger number of volunteers as well as individuals at initial viremia stages would be of interest, together with the follow up of these patients to assess whether after HCV clearance with DAAs, the immunological profile of the CHC patients is recovered. Additionally, to properly demonstrate correlation between the immunophenotype and plasma immune biomarkers’ production, T-cell functionality could be examined by intra-cellular staining for relevant cytokines as well as surface staining of chemokine receptors, such as CCR2, CCR3 or CCR11 corresponding with the observed upregulated chemokines in CHC-CC group. However, the strengths of this study lie in the use of very well characterized cohort, together with appropriate statistical models adjusted for clinical and epidemiological covariates, improving the robustness of our results. Conclusions PWH with CHC harbouring the favourable genotype for HCV clearance (rs12979860-CC genotype) showed a persistent activation, exhaustion and senescence of CD8+ T-cell immune response, that may be masked during clinical monitoring with the higher ability to buffer the excess oxidative stress generated by chronic HCV infection and higher levels of anti and pro-inflammatory plasma molecules. Altogether, shows that once chronic HCV infection has established, CC genotype might result in an unfavourable environment. Supplementary Information Additional file1 (DOCX 889 KB) Additional file1 (DOCX 889 KB)